Video

Optimizing Radiation Therapy in Hodgkin Lymphoma

For High-Definition, Click

Long-term side effects are the leading concern when administering radiation therapy in early-stage Hodgkin lymphoma. However, these side effects often do not manifest for 10 to 20 years following treatment, which complicates studies examining optimal treatment approaches. As a result, Jonathan W. Friedberg, MD, believes that long-term follow-up from trials examining first-line treatment approaches will be more revealing than shorter analyses.

The standard approach for administering radiation has evolved significantly from extended-field radiation to the current standard of involved-field radiation, Craig H. Moskowitz, MD says. This new approach applies radiation only to the affected lymph node, which has been shown to be equally effective and less toxic than extended-field radiation. Longer follow up is still pending to ascertain if these approaches reduce the occurrence of long-term side effects.

Related Videos
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.